In addition, gastrointestinal cancer, NSCLC, endometrial cancer, and urothelial carcinoma also express HER2 on the cell surface, and early clinical trials have been conducted with HER2-targeted ADC drugs (Tsurutani et al., 2020). The gene discussed is ERBB2; the disease is urothelial carcinoma.